oncology
Breast Cancer

Choice of anastrozole v tamoxifen all about the AEs

The IBIS-II DCIS study has failed to show any significant differences in the rate of recurrence in postmenopausal women with DCIS who receive anastrozole versus tamoxifen after their surgery. The study, presented during the 2020 San Antonio Breast Cancer Symposium, randomised 2980 women from 238 centres in 17 countries including Australia to five years of ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic